Ovid Therapeutics Inc OVID:NASDAQ

RT Quote | NASDAQ | USD
Last | 09/22/21 EDT
3.40quote price arrow up+0.02 (+0.59%)
Volume
96,939
52 week range
2.25 - 6.98
Loading...
  • Open3.43
  • Day High3.43
  • Day Low3.35
  • Prev Close3.40
  • 52 Week High6.98
  • 52 Week High Date12/01/20
  • 52 Week Low2.25
  • 52 Week Low Date12/29/20

Key Stats

  • Market Cap230.96M
  • Shares Out67.93M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change47.19

KEY STATS

  • Open3.43
  • Day High3.43
  • Day Low3.35
  • Prev Close3.40
  • 52 Week High6.98
  • 52 Week High Date12/01/20
  • 52 Week Low2.25
  • 52 Week Low Date12/29/20
  • Market Cap230.96M
  • Shares Out67.93M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change47.19

RATIOS/PROFITABILITY

  • EPS (TTM)1.68
  • P/E (TTM)2.03
  • Fwd P/E (NTM)-4.70
  • EBITDA (MRQ)124.54M
  • ROE (MRQ)98.60%
  • Revenue (MRQ)221.00M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)55.10%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ovid Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. The Company's product pipeline includes two late-stage programs and several early-stage programs. The product candidates in its pipeline includes OV935 (soticlestat), OV329, OV882 and OV815. Soticlestat, which is under late-stage program, is for the treatment of dravet syndrome and lennox-gastaut syndrome. OV329, which...
Jeremy Levin
Chairman
Amit Rakhit M.D.
President
Jeffrey Rona
Chief Financial Officer
Address
1460 Broadway Ste 15044
New York, NY
10036-7329
United States

Top Peers

SYMBOLLASTCHG%CHG
AKBA
Akebia Therapeutics Inc
2.81-0.04-1.40%
PBYI
Puma Biotechnology Inc
6.63-0.07-1.04%
CLVS
Clovis Oncology Inc
4.44UNCHUNCH
ATNX
Athenex Inc
3.31-0.03-0.90%
HBIO
Harvard Bioscience Inc
7.65-0.05-0.65%